GoodRx Holdings, Inc., through its subsidiaries, provides information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. More Details
No risks detected for GDRX from our risk checks.
Exceptional growth potential with adequate balance sheet.
Share Price & News
How has GoodRx Holdings's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: GDRX is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: GDRX's weekly volatility (7%) has been stable over the past year.
7 Day Return
US Healthcare Services
1 Year Return
US Healthcare Services
Return vs Industry: Insufficient data to determine how GDRX performed against the US Healthcare Services industry.
Return vs Market: Insufficient data to determine how GDRX performed against the US Market.
Long-Term Price Volatility Vs. Market
How volatile is GoodRx Holdings's share price compared to the market and industry in the last 5 years?
Simply Wall St News
3 months ago | Simply Wall StIs There An Opportunity With GoodRx Holdings, Inc.'s (NASDAQ:GDRX) 29% Undervaluation?
6 months ago | Simply Wall StCan GoodRx Holdings, Inc. (NASDAQ:GDRX) Improve Its Returns?
Is GoodRx Holdings undervalued compared to its fair value and its price relative to the market?
Undervalued compared to fair value
Share Price vs. Fair Value
Below Fair Value: GDRX ($31.64) is trading below our estimate of fair value ($73.89)
Significantly Below Fair Value: GDRX is trading below fair value by more than 20%.
Price To Earnings Ratio
PE vs Industry: GDRX is unprofitable, so we can't compare its PE Ratio to the US Healthcare Services industry average.
PE vs Market: GDRX is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate GDRX's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: GDRX is overvalued based on its PB Ratio (16.6x) compared to the US Healthcare Services industry average (6.3x).
How is GoodRx Holdings forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: GDRX is forecast to become profitable over the next 3 years, which is considered faster growth than the savings rate (2%).
Earnings vs Market: GDRX is forecast to become profitable over the next 3 years, which is considered above average market growth.
High Growth Earnings: GDRX's is expected to become profitable in the next 3 years.
Revenue vs Market: GDRX's revenue (28% per year) is forecast to grow faster than the US market (9.2% per year).
High Growth Revenue: GDRX's revenue (28% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: GDRX's Return on Equity is forecast to be high in 3 years time (24.1%)
How has GoodRx Holdings performed over the past 5 years?
Last years earnings growth
Earnings and Revenue History
Quality Earnings: GDRX is currently unprofitable.
Growing Profit Margin: GDRX is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if GDRX's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare GDRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: GDRX is unprofitable, making it difficult to compare its past year earnings growth to the Healthcare Services industry (32.9%).
Return on Equity
High ROE: GDRX has a negative Return on Equity (-42.63%), as it is currently unprofitable.
How is GoodRx Holdings's financial position?
Financial Position Analysis
Short Term Liabilities: GDRX's short term assets ($1.1B) exceed its short term liabilities ($63.0M).
Long Term Liabilities: GDRX's short term assets ($1.1B) exceed its long term liabilities ($698.9M).
Debt to Equity History and Analysis
Debt Level: GDRX's debt to equity ratio (88.9%) is considered high.
Reducing Debt: Insufficient data to determine if GDRX's debt to equity ratio has reduced over the past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: Whilst unprofitable GDRX has sufficient cash runway for more than 3 years if it maintains its current positive free cash flow level.
Forecast Cash Runway: GDRX is unprofitable but has sufficient cash runway for more than 3 years, due to free cash flow being positive and growing by 27.6% per year.
What is GoodRx Holdings's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate GDRX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate GDRX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if GDRX's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if GDRX's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of GDRX's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Doug Hirsch (50 yo)
Mr. Douglas J. Hirsch, also known as Doug, serves as Co-Chief Executive Officer of GoodRx Holdings, Inc. since January 2015 and it’s a Director since September 2011. Mr. Hirsch is a Co-Founder of GoodRx, I...
CEO Compensation Analysis
Compensation vs Market: Doug's total compensation ($USD267.65M) is above average for companies of similar size in the US market ($USD11.16M).
Compensation vs Earnings: Doug's compensation has increased whilst the company is unprofitable.
Experienced Management: GDRX's management team is not considered experienced ( 1.8 years average tenure), which suggests a new team.
Experienced Board: GDRX's board of directors are considered experienced (5.5 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: GDRX only recently listed within the past 12 months.
GoodRx Holdings, Inc.'s company bio, employee growth, exchange listings and data sources
- Name: GoodRx Holdings, Inc.
- Ticker: GDRX
- Exchange: NasdaqGS
- Founded: 2015
- Industry: Health Care Technology
- Sector: Healthcare
- Market Cap: US$12.433b
- Shares outstanding: 392.95m
- Website: https://www.goodrx.com
Number of Employees
- GoodRx Holdings, Inc.
- 2701 Olympic Boulevard
- Suite 990
- Santa Monica
- United States
GoodRx Holdings, Inc., through its subsidiaries, provides information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company opera...
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/08/03 23:45|
|End of Day Share Price||2021/08/03 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.